TAVR(경피적 대동맥판막 치환술) 시장 기회, 성장 촉진요인, 업계 동향 분석 및 예측(2026-2035년)

The Global TAVR (Transcatheter Aortic Valve Replacement) Market was valued at USD 6.6 billion in 2025 and is estimated to grow at a CAGR of 9.8% to reach USD 16.5 billion by 2035.

The TAVR (Transcatheter Aortic Valve Replacement) market continues to experience strong growth as transcatheter valve procedures become an increasingly preferred treatment option for patients with aortic stenosis across a broader range of clinical risk categories. Expanding clinical evidence demonstrating favorable patient outcomes compared with conventional treatment approaches continues to support wider physician acceptance and procedural adoption. Long-term market expansion is further driven by the rapid growth of the aging population, increasing prevalence of cardiovascular disorders, and ongoing improvements in healthcare reimbursement across developed economies. Advances in valve technology, enhanced procedural planning, and continuous innovation in imaging capabilities are improving treatment precision while supporting broader clinical application. As life expectancy rises worldwide, the number of patients eligible for transcatheter valve replacement continues to increase, creating sustained demand for minimally invasive cardiac interventions. Healthcare systems across North America, Europe, and Asia Pacific are also expanding access to advanced cardiovascular care, encouraging higher procedural volumes and reinforcing favorable long-term growth prospects for the global TAVR (Transcatheter Aortic Valve Replacement) market.

The balloon-expandable valves segment accounted for 55% share in 2025 and is projected to grow at a CAGR of 9.6% through 2035, making them the leading deployment type. The segment maintains its dominant position because balloon-expandable systems provide highly accurate valve placement, reliable deployment performance, and consistent hemodynamic outcomes. Their established clinical performance, long-term durability, and predictable procedural characteristics continue to support widespread adoption among healthcare providers, contributing significantly to procedural growth across the global market.

The hospitals segment held 82% share in 2025 and is expected to grow at a CAGR of 9.6% during 2026-2035. Hospital settings remain the primary end users because transcatheter valve replacement procedures require advanced cardiac catheterization facilities, multidisciplinary clinical teams, specialized patient monitoring capabilities, and comprehensive emergency care infrastructure. High-volume cardiovascular treatment centers continue to perform the majority of procedures, supported by experienced clinical teams and well-established structural heart programs that ensure safe and effective patient care.

North America TAVR (Transcatheter Aortic Valve Replacement) Market accounted for 46% share in 2025 and is projected to grow at a CAGR of 9.6% through 2035. The United States remains the largest contributor to regional demand, while Canada also represents an important market supported by its established healthcare system. Market growth across the region continues to benefit from favorable reimbursement policies, expanding patient eligibility, growing physician adoption, and increasing availability of specialized treatment centers, all of which continue to support higher procedural volumes and sustained market expansion.

Major companies operating in the Global TAVR (Transcatheter Aortic Valve Replacement) market include Medtronic, Edwards Lifesciences, Abbott Laboratories, Boston Scientific Corporation, LEPU Medical, MicroPort, Venus Medtech, Meril Life Sciences, Peijia Medical, JenaValve Technology, Foldax, Bracco, and Anteris Technologies. Companies operating in the TAVR (Transcatheter Aortic Valve Replacement) market are strengthening their competitive position by investing heavily in research and development to improve valve performance, procedural safety, and long-term clinical outcomes. Manufacturers continue to expand product portfolios through technological innovation while focusing on minimally invasive treatment solutions that improve physician confidence and patient recovery. Strategic collaborations with healthcare providers, clinical research organizations, and academic institutions are supporting product development and expanding clinical adoption.

Table of Contents

Chapter 1 Research Methodology

• 1.1 Market definitions
• 1.2 Research approach
• 1.3 Quality commitments
  • 1.3.1 GMI AI policy & data integrity commitment
    • 1.3.1.1 Source consistency protocol
• 1.4 Research trail & confidence scoring
  • 1.4.1 Research trail components
  • 1.4.2 Scoring components
• 1.5 Data collection
  • 1.5.1 Partial list of primary sources
• 1.6 Data mining sources
  • 1.6.1 Paid sources
    • 1.6.1.1 Sources, by region
• 1.7 Base estimates and calculations
  • 1.7.1 Base year calculation
• 1.8 Forecast model
  • 1.8.1 Quantified market impact analysis
    • 1.8.1.1 Mathematical impact of growth parameters on forecast
• 1.9 Research transparency addendum
  • 1.9.1 Source attribution framework
  • 1.9.2 Quality assurance metrics
  • 1.9.3 Our commitment to trust

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
• 2.2 Key market trends
  • 2.2.1 Regional trends
  • 2.2.2 Deployment type trends
  • 2.2.3 Implantation procedures trends
  • 2.2.4 Material trends
  • 2.2.5 End use trends
• 2.3 CXO perspectives: Strategic imperatives

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing Elderly Population
    • 3.2.1.2 Advancements in TAVR Technology
    • 3.2.1.3 Shift Toward Minimally Invasive Procedures
    • 3.2.1.4 Improved Reimbursement and Insurance Coverage
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High Cost of TAVR Devices
    • 3.2.2.2 Risk of Complications
  • 3.2.3 Opportunities
    • 3.2.3.1 Next generation device launches with extended durability
    • 3.2.3.2 Expansion in Asia Pacific and other emerging markets
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pricing analysis, 2025
• 3.6 Technology and innovation landscape (Driven by Primary Research)
  • 3.6.1 Current technological trends
  • 3.6.2 Emerging technologies
• 3.7 Investment landscape
• 3.8 Reimbursement scenario
• 3.9 Future market trends (Driven by Primary Research)
• 3.10 Evolution of TAVR devices by generation
• 3.11 Impact of AI & Generative AI on the Market (Driven by Primary Research)
• 3.12 Porter's analysis
• 3.13 PESTEL analysis

Chapter 4 Competitive Landscape, 2025

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis (Driven by Primary Research)
  • 4.3.1 Global
  • 4.3.2 North America
  • 4.3.3 Europe
  • 4.3.4 Asia Pacific
  • 4.3.5 LAMEA
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Mergers & acquisitions
  • 4.6.2 Partnerships & collaborations
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Deployment Type, 2022 - 2035 ($ Mn)

• 5.1 Key trends
• 5.2 Balloon-expandable valves
• 5.3 Self-expanding valves
• 5.4 Mechanically expanded valves

Chapter 6 Market Estimates and Forecast, By Implantation Procedures, 2022 - 2035 ($ Mn)

• 6.1 Key trends
• 6.2 Transfemoral
• 6.3 Transapical
• 6.4 Transaortic

Chapter 7 Market Estimates and Forecast, By Material, 2022 - 2035 ($ Mn)

• 7.1 Key trends
• 7.2 Nitinol
• 7.3 Stainless steel
• 7.4 Cobalt chromium
• 7.5 Other materials

Chapter 8 Market Estimates and Forecast, By End Use, 2022 - 2035 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals
• 8.3 Ambulatory Surgical Centers
• 8.4 Other end users

Chapter 9 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 MEA
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 Abbott Laboratories
• 10.2 Anteris Technologies
• 10.3 Boston Scientific Corporation
• 10.4 Bracco
• 10.5 Edwards Lifesciences
• 10.6 Foldax
• 10.7 JenaValve Technology
• 10.8 LEPU Medical
• 10.9 Medtronic
• 10.10 Meril Life Sciences
• 10.11 MicroPort
• 10.12 Peijia Medical
• 10.13 Venus Medtech